Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents

Chong, Yong Pil; Tani, Naoki; Goto, Takafumi; Yonekawa, Akiko; Ikematsu, Hideyuki; Shimono, Nobuyuki; Tanaka, Yosuke; Akashi, Koichi

doi:10.1016/j.jinf.2021.10.011

Cited by 10 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show that a modified threshold for nucleoprotein-IgG, of 0.5 S/CO instead of the 1.4 S/CO threshold proposed by the manufacturer, had a stronger predictive value for a high humoral response to the first dose. Our results also found that the second factor associated with a higher RBD-IgG response was a longer delay between infection and vaccination, confirming previous results 38,39 . Strong anamnestic responses require an interval of at least 4 months between primary and secondary immune responses 40 www.nature.com/scientificreports/ plasma cells.…”

Section: Discussionsupporting

confidence: 92%

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents

Tuaillon

Pisoni

Veyrenche

et al. 2022

Sci Rep

View full text Add to dashboard Cite

We explored antibody response after first and second BNT162b2 vaccinations, to predict the need for subsequent injections in nursing home (NH) residents. 369 NH residents were tested for IgG against SARS-CoV-2 Receptor-Binding Domain (RBD-IgG) and nucleoprotein-IgG (SARS-CoV-2 IgG II Quant and SARS-CoV-2 IgG Alinity assays, Abbott Diagnostics). In NH residents with prior SARS-CoV-2 infection, the first dose elicited high RBD-IgG levels (≥ 4160 AU/mL) in 99/129 cases (76.9%), with no additional antibody gain after the second dose in 74 cases (74.7%). However, a low RBD-IgG level (< 1050 AU/mL) was observed in 28 (21.7%) residents. The persistence of nucleoprotein-IgG and a longer interval between infection and the first dose were associated with a higher RBD-IgG response (p < 0.0001 and p = 0.0013, respectively). RBD-IgG below 50 AU/mL after the first dose predicted failure to reach the antibody concentration associated with a neutralizing effect after the second dose (≥ 1050 AU/mL). The BNT162b2 vaccine elicited a strong humoral response after the first dose in a majority of NH residents with prior SARS-CoV-2 infection. However, about one quarter of these residents require a second injection. Consideration should be given to immunological monitoring in NH residents to optimize the vaccine response in this vulnerable population.

show abstract

Section: Discussionsupporting

confidence: 92%

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents

Tuaillon

Pisoni

Veyrenche

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…It indicated that a single dose of inactivated vaccine induced strong NAbs and virus-specific T-cell response and the second booster immunization did not further increase the strength of NAbs or T cell immunity in COVID-19 convalescents. Similar results were found in convalescent patients who received the COVID-19 mRNA vaccine ( Chong et al., 2021 ; Havervall et al., 2021 ; Krammer et al., 2021 ; Manisty et al., 2021 ; Lim et al., 2022 ). Joseph et al.…”

Section: Discussionsupporting

confidence: 81%

“…Several studies reported humoral immunity to a single or two doses of messenger RNA (mRNA) vaccines and adenovirus-vectored vaccines in subjects previously infected with SARS-CoV-2 ( Chong et al., 2021 ; Ebinger et al., 2021 ; Goel et al., 2021 ; Havervall et al., 2021 ; Krammer et al., 2021 ; Manisty et al., 2021 ; Reynolds et al., 2021 ; Saadat et al., 2021 ; Lim et al., 2022 ). These COVID-19 convalescents developed strong spike-specific IgG and neutralizing antibodies (NAbs) after one dose that were equivalent to or exceeding those naïve recipients after two-dose vaccination ( Ebinger et al., 2021 ; Goel et al., 2021 ; Havervall et al., 2021 ; Krammer et al., 2021 ; Manisty et al., 2021 ; Reynolds et al., 2021 ; Saadat et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Neutralizing antibodies and T-cell responses to inactivated SARS-CoV-2 vaccine in COVID-19 convalescents one and a half years after infection

Yan

Wang

et al. 2023

Virus Research

View full text Add to dashboard Cite

“…This study was conducted as a serological follow‐up evaluation after reporting specific antibody responses after the initial SARS‐CoV‐2 vaccine series at a nursing home with an outbreak in April, 2020 12 . In the same cohort, individuals whose samples were obtained 6 months after the second dose and shortly after the third dose were included.…”

Section: Methodsmentioning

confidence: 99%

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents

Chong

Goto

Tani

et al. 2022

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

Background Infection control during COVID‐19 outbreaks in nursing facilities is a critical public health issue. Antibody responses before and after the third (booster) dose of SARS‐CoV‐2 vaccination in nursing home residents have not been fully characterized. Methods This study included 117 individuals: 54 nursing home residents (mean age, 83.8 years; 39 SARS‐CoV‐2‐naive and 15 previously infected) and 63 healthcare workers (mean age, 45.8 years; 32 SARS‐CoV‐2‐naive and 31 previously infected). Anti‐spike (receptor‐binding domain [RBD]) and anti‐nucleocapsid antibody responses to BNT162b2 mRNA vaccination and their related factors were evaluated using pre‐ (shortly and 6 months after the second dose) and post‐booster vaccination samples. Results The median anti‐spike (RBD) IgG level in SARS‐CoV‐2‐naive residents 6 months after the second dose was the lowest among the four groups, with a decreasing rate of over 90%. The median rate of increase before and after the third dose in SARS‐CoV‐2‐naive residents was significantly higher than that in SARS‐CoV‐2‐naive healthcare workers (64.1‐ vs. 37.0‐fold, P = 0.003), with the highest level among the groups. The IgG ratio of SARS‐CoV‐2‐naive residents to healthcare workers after the second and third doses changed from one‐fifth (20%) to one‐half (50%). The rate of increase after the third dose in previously infected individuals was three‐ to fourfold, regardless of residents or healthcare workers. Conclusions Advanced aged nursing home residents, poor responders in the initial SARS‐CoV‐2 vaccine series, could obtain sufficient antibody responses with the additional booster dose, despite more than 6 months after the second.

show abstract

Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents

Cited by 10 publications

References 11 publications

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents

Neutralizing antibodies and T-cell responses to inactivated SARS-CoV-2 vaccine in COVID-19 convalescents one and a half years after infection

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents

Contact Info

Product

Resources

About